Prof. Karl-Heinz Altmann awarded the Paul Ehrlich Prize 2014
"The French Medicinal Chemistry Society (SCT) and Janssen-Cilag S.A. are very pleased to annonce that the Paul Ehrlich Prize 2014 is attributed to Professor Karl-Heinz ALTMANN (Institut of Pharmaceutical Sciences, ETH Zürich, Switzerland) recognizing his outstanding contribution and substantial results in the field of the chemistry and chemical biology of pharmaceutically relevant natural products and analogs.
Professor Altmann will deliver a plenary lecture at the 50th International Conference on Medicinal Chemistry (RICT 2014) in Rouen, Normandy, on July 2-4 2014.
For more information on RICT 2014, see: www.sct-asso.fr
The Swiss Chemical Society thanks Prof. Altmann for his outstanding, scientific contributions and contratulates on this honorable award.
Karl-Heinz Altmann is a Member of the SCS divisional board of Medicinal Chemistry & Chemical Biology and was its President from 2011 - 2013.
Website of Prof. Karl-Heinz Altmann, Inst. f. Pharmazeutische Wiss. ,ETH Zürich
David Spichiger, SCS
19.06.2014
Preview: 3rd Japanese-Swiss Chemical Biology Symposium
3rd Japanese-Swiss Chemical Biology Symposium
University of Berne, Departmen of Chemistry and Biochemistry
Freiestrasse 3, 3012 Bern, Lecture Room EG16
Thu, October 2, 2014, 10:15 - Fri October 3, 2014, 17:30
Topics of the Symposium:
- Drug Design
- Peptides and Foldamers
- Nucleic Acids
- Imaging
- Biological Membranes
- Natural Products
Contact (Scientific Committee)
- Jean-Louis Reymond (University of Bern, Chair)
- Tamis Darbre (University of Bern)
More information
Website: http://www.sjchembio2014.unibe.ch
David Spichiger, SCS
12.06.2014
Mini Symposium: Kinetics and Thermodynamics in Drug Discovery: May 22, 2014
Mini-Symposium
«Kinetics and Thermodynamics in Drug Discovery»
Thursday, May 22, 2014, 13:30 - 17:45
Big Lecture Hall, Department of Chemistry
University of Basel, St. Johanns-Ring 19
This year's annual mini-symposium organized by the Division of Medicinal Chemistry & Chemical Biology of the Swiss Chemical Society is dedicated to the topic of Kinetics and Thermodynamics in Drug Discovery.
This free event is gathering five globally renowed experts in the field that will showcase the importance of this topic in drug discovery.
Program
| 13.30h | Introduction |
| 13.35h | Gerhard Klebe, University of Marburg Correlation of structure, thermodynamics and molecular dynamics to better understand drug binding |
| 14.20h | David Swinney, Institute for Rare and Neglected Diseases Drug Discovery Application of binding kinetics to drug discovery |
| 15.05h | Coffee Break |
| 15.30h | Göran Dahl, AstraZeneca Pharmacokinetics and the drug-target residence time concept |
| 16.15h | David Sykes, Novartis Institutes for Biomedical Research Exploring the relationship between β2-adrenoceptor drug binding affinity/kinetic constants and physicochemical parameters |
| 17.00 | Russel Petter, Celgene Design and optimization of targeted covalent inhibitors |
Poster
Contact
Nikolaus Stiefl
Novartis Pharma AG
Forum1, Novartis Campus
4056 Basel
Email:
Registration
No registration – free admission
Sponsors
 |
 |
 |
 |
David Spichiger, SCS
07.03.2014
Kinetics and Thermodynamics in Drug Discovery: May 22, 2014
Big Lecture Hall, Department of Chemistry
University of Basel, St. Johanns-Ring 19
May 22, 2014, 13.30-17.45
This year's annual mini-symposium organized by the Division of Medicinal Chemistry & Chemical Biology of the Swiss Chemical Society is dedicated to the topic of Kinetics and Thermodynamics in Drug Discovery.
This free event is gathering five globally renowed experts in the field that will showcase the importance of this topic in drug discovery.
Program
| 13:30–13:35 | Introduction |
| 13:35–14:20 |
Gerhard Klebe, University of Marburg Correlation of Structure, Thermodynamics and Molecular Dynamics to Better Understand Drug Binding |
| 14:20–15:05 |
David Swinney, iRND3 Application of binding kinetics to drug discovery |
| 15:05–15:30 | Coffee Break |
| 15:30–16:15 |
Göran Dahl, AstraZeneca Pharmacokinetics and the drug-target residence time concept |
| 16:15–17:00 |
David Sykes, Novartis Institutes for Biomedical Research Exploring the relationship betweenb2 adrenoceptor drug binding affinity/kinetic constants and physicochemical parameters |
| 17:00–17:45 |
Russel Petter, Celgene Design and Optimization of Targeted Covalent Inhibitors |
Contact
Herr Dr. Nikolaus Stiefl
Novartis Pharma AG
Forum1, Novartis Campus
4056 Basel
David Spichiger, SCS
03.02.2014
Call for nominations: EFMC 2014 Awards
The awards will be conferred on the occasion of the XXIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC), to be held in Lisbon, Portugal, September 7-11, 2014
|
For the advancement of medicinal chemistry and the development of international organisational structures in Medicinal Chemistry. The Award will be given for outstanding achievements in the field of Medicinal Chemistry.
|
|
To acknowledge and recognize outstanding research in the field of Medicinal Chemistry in its broadest sense by a young scientist. This Award has been established with the support of UCB Pharma.
|
|
The Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery |
To encourage innovation and investigation in technological development related to drug discovery, this Award established with the support of Prous Institute will be given for the discovery, evaluation or use of new technologies.
|
Nominations for these Awards consist of a nomination letter, a brief CV, including a list of selected publications and two supporting letters. Self-nominations are also accepted. The nominations should be submitted to the Chairman of the Juries, Dr Hans Ulrich Stilz, President of EFMC, c\o EFMC Administrative Secretariat, Rue Michel de Ghelderode 33/2, 1348, Louvain-la-Neuve, Belgium. Fax: +32 10 45 97 19 E-mail: .
Please visit www.efmc.info for more information and Awards regulations.
Page 276 of 299